Fresenius Claims Edge With US Tocilizumab Biosimilar Approval
German Firm’s Tyenne Rival To Actemra Wins FDA Nod In Both IV And SC Presentations
Fresenius Kabi has claimed an advantage in the biosimilar tocilizumab arena after its Tyenne rival to Actemra was approved by the US FDA in both intravenous and subcutaneous formulations.
